Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 153

1.

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).

Johnen A, Bürkner PC, Landmeyer NC, Ambrosius B, Calabrese P, Motte J, Hessler N, Antony G, König IR, Klotz L, Hoshi MM, Aly L, Groppa S, Luessi F, Paul F, Tackenberg B, Bergh FT, Kümpfel T, Tumani H, Stangel M, Weber F, Bayas A, Wildemann B, Heesen C, Zettl UK, Zipp F, Hemmer B, Meuth SG, Gold R, Wiendl H, Salmen A; German Competence Network Multiple Sclerosis (KKNMS).

J Neurol. 2019 Feb;266(2):386-397. doi: 10.1007/s00415-018-9142-y. Epub 2018 Dec 4.

PMID:
30515631
2.

Disease Modification in Multiple Sclerosis by Flupirtine-Results of a Randomized Placebo Controlled Phase II Trial.

Dörr J, Wernecke KD, Würfel J, Bellmann-Strobl J, Siffrin V, Sättler MB, Simons M, Linsa A, Tumani H, Paul F.

Front Neurol. 2018 Oct 9;9:842. doi: 10.3389/fneur.2018.00842. eCollection 2018.

3.

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Krumbholz M, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl UK, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; NEMOS (Neuromyelitis Optica Study Group).

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504. doi: 10.1212/NXI.0000000000000504. eCollection 2018 Nov.

4.

Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk.

International Multiple Sclerosis Genetics Consortium. Electronic address: chris.cotsapas@yale.edu; International Multiple Sclerosis Genetics Consortium.

Cell. 2018 Nov 29;175(6):1679-1687.e7. doi: 10.1016/j.cell.2018.09.049. Epub 2018 Oct 18.

5.

Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis.

Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, Tumani H, von Arnim CAF, Dorst J, Feneberg E, Mayer B, Müller HP, Gorges M, Rosenbohm A, Volk AE, Silani V, Ludolph AC, Otto M.

J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):157-164. doi: 10.1136/jnnp-2018-318704. Epub 2018 Oct 11.

PMID:
30309882
6.

Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: a prospective study in 17 patients.

Dorst J, Ludolph AC, Senel M, Tumani H.

J Neurol. 2018 Dec;265(12):2906-2915. doi: 10.1007/s00415-018-9082-6. Epub 2018 Oct 6.

PMID:
30293110
7.

Comprehensive microRNA expression profiling in cerebrospinal fluid distinguishes between neurological disease classes.

Grasedieck S, Mulaw M, Sperb N, Wessinger K, Rouhi A, Bommer M, Bromberg JEC, Otto M, Tumani H, von Arnim CAF, Mertens D, Kuchenbauer F.

Neuropathol Appl Neurobiol. 2018 Apr 21. doi: 10.1111/nan.12491. [Epub ahead of print] No abstract available.

PMID:
29679382
8.

Intrathecal immunoglobulin M production: A promising high-risk marker in clinically isolated syndrome patients.

Huss A, Abdelhak A, Halbgebauer S, Mayer B, Senel M, Otto M, Tumani H.

Ann Neurol. 2018 May;83(5):1032-1036. doi: 10.1002/ana.25237. Epub 2018 May 11.

PMID:
29665046
9.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Erratum in: Lancet. 2018 Nov 17;392(10160):2170.

PMID:
29576505
10.

Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis.

Mueller SH, Färber A, Prüss H, Melzer N, Golombeck KS, Kümpfel T, Thaler F, Elisak M, Lewerenz J, Kaufmann M, Sühs KW, Ringelstein M, Kellinghaus C, Bien CG, Kraft A, Zettl UK, Ehrlich S, Handreka R, Rostásy K, Then Bergh F, Faiss JH, Lieb W, Franke A, Kuhlenbäumer G, Wandinger KP, Leypoldt F; German Network for Research on Autoimmune Encephalitis (GENERATE).

Ann Neurol. 2018 Apr;83(4):863-869. doi: 10.1002/ana.25216.

PMID:
29572931
11.

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation.

Teunissen CE, Otto M, Engelborghs S, Herukka SK, Lehmann S, Lewczuk P, Lleó A, Perret-Liaudet A, Tumani H, Turner MR, Verbeek MM, Wiltfang J, Zetterberg H, Parnetti L, Blennow K.

Alzheimers Res Ther. 2018 Mar 15;10(1):30. doi: 10.1186/s13195-018-0359-x. Review.

12.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

13.

Development and Validation of an Ultrasensitive Procalcitonin Sandwich Immunoassay.

Carcamo Yañez VA, Göpfert JC, Otto M, Tumani H, Peter A, Joos TO.

High Throughput. 2017 Nov 16;6(4). pii: E18. doi: 10.3390/ht6040018.

14.

Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression.

Steinacker P, Verde F, Fang L, Feneberg E, Oeckl P, Roeber S, Anderl-Straub S, Danek A, Diehl-Schmid J, Fassbender K, Fliessbach K, Foerstl H, Giese A, Jahn H, Kassubek J, Kornhuber J, Landwehrmeyer GB, Lauer M, Pinkhardt EH, Prudlo J, Rosenbohm A, Schneider A, Schroeter ML, Tumani H, von Arnim CAF, Weishaupt J, Weydt P, Ludolph AC, Yilmazer Hanke D, Otto M; FTLDc study group.

J Neurol Neurosurg Psychiatry. 2018 Mar;89(3):239-247. doi: 10.1136/jnnp-2017-317138. Epub 2017 Nov 15.

PMID:
29142138
15.

Preface.

Deisenhammer F, Teunissen CE, Tumani H.

Handb Clin Neurol. 2017;146:ix. doi: 10.1016/B978-0-12-804279-3.09987-1. No abstract available.

PMID:
29110783
16.

Epilepsy.

Fauser S, Tumani H.

Handb Clin Neurol. 2017;146:259-266. doi: 10.1016/B978-0-12-804279-3.00015-0. Review.

PMID:
29110774
17.

The cerebrospinal fluid and barriers - anatomic and physiologic considerations.

Tumani H, Huss A, Bachhuber F.

Handb Clin Neurol. 2017;146:21-32. doi: 10.1016/B978-0-12-804279-3.00002-2. Review.

PMID:
29110772
18.

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.

Ziemssen T, Tumani H, Sehr T, Thomas K, Paul F, Richter N, Samara E, Spiegelstein O, Sorani E, Bar-Ilan O, Mimrod D, Hayardeny L.

J Neuroinflammation. 2017 Aug 31;14(1):172. doi: 10.1186/s12974-017-0945-z.

19.

GFAP in early multiple sclerosis: A biomarker for inflammation.

Kassubek R, Gorges M, Schocke M, Hagenston VAM, Huss A, Ludolph AC, Kassubek J, Tumani H.

Neurosci Lett. 2017 Sep 14;657:166-170. doi: 10.1016/j.neulet.2017.07.050. Epub 2017 Aug 9.

PMID:
28802830
20.

CSF profile in primary progressive multiple sclerosis: Re-exploring the basics.

Abdelhak A, Hottenrott T, Mayer C, Hintereder G, Zettl UK, Stich O, Tumani H.

PLoS One. 2017 Aug 10;12(8):e0182647. doi: 10.1371/journal.pone.0182647. eCollection 2017.

Supplemental Content

Loading ...
Support Center